Table 3.
Urinary biomarkers for the early prediction of clinical outcomes in various AKI settings
| Biomarker name | Cardiopulmonary bypass (CPB) | Kidney transplant | Intensive care or emergency setting |
|---|---|---|---|
| NGAL | Predicts AKI duration, severity, dialysis and death | Predicts AKI duration | Predicts AKI duration, severity and dialysis |
| References | [41,42] | [27] | [34,36,43] |
| IL-18 | Predicts AKI duration | Predicts AKI duration | Predicts death |
| References | [22] | [27] | [66] |
| KIM-1 | Not tested | Predicts long-term graft loss | Predicts dialysis and death |
| References | [67] | [68] |
NGAL, neutrophil gelatinase-associated lipocalin; IL-18, interleukin 18; KIM-1, kidney injury molecule 1.
AKI is defined as a 50% or greater increase in serum creatinine from baseline.